For example, in 5-fluorouracil (5-FU)-resistant colorectal cancer, the METTL3 inhibitor STM2457 restores sensitivity to 5-FU by repressing glycolysis in CRC cells, whereas the LDHA inhibitor FX11 effectively reduces lactate production. This evidence concerns the gene METTL3 and colorectal carcinoma.